

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE (I-MAK), INC.
Petitioner

v.

GILEAD PHARMASSET LLC
Patent Owner

Case No. IPR2018-00211
U.S. Patent No. 9,393,256

DECLARATION OF JOSEPH M. FORTUNAK, Ph.D.

TABLE OF CONTENTS

| | | |
|-------|--|----|
| I. | QUALIFICATIONS | 1 |
| II. | SCOPE OF WORK..... | 7 |
| III. | OVERVIEW OF THE '256 PATENT | 8 |
| IV. | FILE HISTORY OF THE '256 PATENT | 9 |
| V. | LEGAL STANDARDS | 10 |
| VI. | PERSON OF ORDINARY SKILL IN THE ART | 11 |
| VII. | CLAIM CONSTRUCTION | 12 |
| VIII. | BACKGROUND KNOWLEDGE IN THE ART | 13 |
| | A. Nucleos(t)ide NS5B Polymerase Inhibitors PSI-7851 and PSI-7977 (Compound 10 in '256) for Treating HCV Were Known..... | 13 |
| | B. Nucleos(t)ide NS5B Polymerase Inhibitors Were Combined With Other Antiviral Agents, Including NS5A Inhibitors, To Treat HCV . | 15 |
| IX. | SCOPE AND CONTENT OF THE PRIOR ART..... | 20 |
| | A. Legrand-Abravanel..... | 20 |
| | B. Delaney..... | 21 |
| | C. Sofia '634 | 23 |
| | D. Guo | 23 |
| X. | PRIOR ART REFERENCES DISCLOSE OR SUGGEST EACH OF THE CLAIMED FEATURES OF THE '256 PATENT | 24 |
| | A. Claims 1-4 Were Anticipated By And Obvious Over Legrand- Abravanel | 24 |
| | B. Claims 1-4 Were Anticipated By Delaney | 27 |

C. Claims 1-4 Were Obvious Over Sofia '634 and Guo31

XI. CONCLUSION.....34

XII. APPENDIX – LIST OF EXHIBITS.....36

I, Joseph M. Fortunak, declare as follows:

I. QUALIFICATIONS

1. My name is Joseph M. Fortunak. I am a Professor of Chemistry and Pharmaceutical Sciences at Howard University, in Washington, D.C., where I regularly teach courses in Organic Chemistry to undergraduate students. I also teach courses in drug discovery, drug development, pharmaceutical chemistry, pharmaceutical sciences, and green chemistry/chemical synthesis to PharmD and PhD students in Chemistry and Pharmacy.

2. I received my Bachelor of Science in Chemistry from Purdue University in 1976, and my Doctorate in Philosophy in Organic Chemistry from the University of Wisconsin-Madison in 1981. After earning my Ph.D., I was a postdoctoral fellow and a research assistant professor at Cambridge University in the United Kingdom from 1981-1983.

3. My career has spanned both the industrial and academic sectors, including senior managerial and academic appointments.

4. From 1983-1993, I worked at SmithKline Beecham Pharmaceutical Corp., and served as Associate Senior Research Investigator, Senior Research Investigator and Assistant Director. During that time, I was primarily responsible for inventing processes to synthesize active pharmaceutical ingredients (“APIs”) for investigational new drugs, including the drugs halofantrine, ropinerole,

topotecan and eprosartan, which the U.S. Food and Drug Administration (“FDA”) has approved.

5. From 1993-2000, I worked at DuPont Pharmaceutical Company (“DuPont”), and served as Associate Director, Director, Senior Director and Executive Director. During my tenure at DuPont, among other responsibilities, I led the API development team for the major anti-HIV drug efavirenz, which is an inhibitor of HIV-1 reverse transcriptase. I was also responsible for building a pre-formulations group of experts in organic, solid-state chemistry (i.e. crystalline forms, polymorphs, solvates, hydrates and amorphous forms), and for managing the interface(s) between the API, Formulations, and Analytical groups at DuPont.

6. From 1993-1999 I also served on the Scientific Advisory Board for NaPro Biotherapeutics in Boulder, Colorado, working on a commercial semi-synthesis of the anti-cancer drug paclitaxel from renewable biomass.

7. From 2000-2004, I worked at Abbott Laboratories as the Head of Global Chemical Development. In that position I was responsible for managing chemistry, engineering, and analytical development for all of Abbott's new drug candidates. During that time, I built a Process Engineering Department with expertise in separation sciences, solids engineering and process modeling. I also was responsible for process validation for four New Drug Applications, including XIENCE™ V drug-device combination (a coronary stent), and emtricitabine, an

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.